Co-Founder, Chairman & Chief Executive Officer, HIMS & HERS HEALTH INC
Search every verified Andrew Dudum interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Andrew Dudum, co-founder and CEO of Hims & Hers Health, discussed the company’s use of artificial intelligence in healthcare during an August 18, 2026 CNBC interview. He described a goal of using technology to lower care costs and standardize access to clinical expertise, and he noted that AI could improve patient adherence to medications. Dudum also commented on the pricing of GLP-1 weight-loss drugs, stating that market competition had reduced monthly costs from around $1,500 to $150 within a year. He proposed providing every American citizen with a health savings account-style budget to create a competitive marketplace for healthcare services. On the company’s second-quarter 2026 earnings call, held August 10-11, 2026, Hims & Hers reported revenue of $753 million, up 40% year over year, and raised its guidance. Dudum said the company was investing in international expansion across markets including Australia, Japan, Canada, Germany, and the UK, and planned to add higher-complexity offerings such as injectable testosterone and, if regulators allow, peptide therapies. He stated that the company was developing a peptide program with U.S.-manufactured products and clinical testing, while awaiting an FDA decision on six peptides recommended at a recent advisory committee hearing. Dudum also said the company now serves nearly 3 million people daily and described it as a comprehensive personal health platform.
In an exclusive interview, Hims & Hers CEO Andrew Dudum sits down with Squawk Box Co-Anchor Andrew Ross Sorkin and shares his perspective on how AI can transform healthcare, the company's transition from compound to brand name GLP-1s, and his vision to bring down the cost of healthcare.
In an exclusive, rare interview, CEO and co-founder of Hims & Hers Andrew Dudum sits down with Andrew Ross Sorkin. Dudum ...
Hims & Hers Health Q2 2026 Earnings Conference Call. Twitter - https://x.com/i101yt If you find our work useful, please support us by purchasing a Super Thanks— it truly helps us a lot. #earningscall #StockMarketNews #conferenceCall Earnings Call | Earnings Conference Call | Earnings concall | concall | quarterly results | Stock News | Full Year results | Fiscal Year results | investment news | stock latest news | Annual Meeting of Shareholders | Annual Meeting of Unitholders | Special and Annual Meeting of Shareholders | AGM | Annual General Meeting If you want us to remove your company…
--------- Hims & Hers Health, Inc HIMS Q2 2026 Earnings Call --------- In this video, we’ll cover the latest quarterly earnings results, key financial metrics, and business highlights from the most recent reporting period. 🔔 Don’t forget to subscribe and follow us on X for more updates: https://x.com/Fyfull2 Disclaimer: This video includes segments from official corporate earnings calls and presentations, used for educational and informational purposes under fair use (Section 107, U.S. Copyright Act). No affiliation or endorsement by the companies mentioned is implied. All content rights…
Today on the Prof G Markets Founder Series, Ed Elson sits down with Andrew Dudum, co-founder and CEO of Hims & Hers, to discuss why the company went public so early, how it made GLP-1s more affordable, and whether healthcare regulation has gone too far. They also explore why Hims & Hers chose to disrupt the system instead of working within it. Timestamps: 00:00 Intro 00:49 Interview with Andrew Dudum 01:42 How was Hims & Hers created? 04:44 Why did Hims & Hers focus on male issues at the beginning? 07:53 How did Hims & Hers get into male issues earlier than anyone else? 12:02 How was the path…
05/11/2026 Q&A: 42:58 Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, an…
Andrew Dudum is the Founder and CEO of Hims, the company reshaping consumers relationship to healthcare. It has been a rocky ride over the last 6 months, the company is down 66%, their market cap today is $4.3BN on $2.3BN of revenue. They just bought their largest international competitor, Eucalyptus for $1.5BN. ----------------------------------------------- Timestamps: 00:00 Intro 01:17 Why Running a Public Company Is More Fun Than Being Private 05:07 How to Hire for Grit: People Who Have Been Through Shit 08:31 Founder Mode vs Trusting Your Team 10:58 How Many Employees Will Hims Have in…
Andrew Dudum built Hims & Hers from zero into a multi-billion-dollar consumer publicly-traded consumer health company by doing something most founders avoid: leaning directly into discomfort. He’s able to lead the hard conversations that most leaders avoid. In this episode, Andrew and I talk candidly about what it actually takes to scale a company and stay grounded while doing it. We unpack the lessons he learned by understanding mortality early, the emotional whiplash of running a public company, and why “being nice” is often the least kind thing a leader can do. Andrew shares the moment at…
Hims & Hers Health Q4 2025 Earnings Conference Call. Twitter - / i101in If you find our work useful, please support us by purchasing a Super Thanks— it truly helps us a lot. #earningscall #StockMarketNews #conferenceCall Earnings Call | Earnings Conference Call | Earnings concall | concall | quarterly results | Stock News | Full Year results | Fiscal Year results | investment news | stock latest news If you want us to remove your company's earnings call or any other conference call, please reach out to [email protected].
📢 Hims & Hers Health Earnings Call Q2 2025 $HIMS 🔍What To Expect: Hims & Hers Health Earnings Preview: https://www.benzinga.com/insights/ear... 💰 STOP READING ABOUT PROFITS – START MAKING THEM! Get financial research that tells you what to buy, when to buy, and why with Benzinga Edge: 🔗 https://www.benzinga.com/premium/idea... 📜 Need a transcript of the call? Access the Benzinga Earnings Call Transcripts API: 🔗 https://www.benzinga.com/apis/cloud-p... 🌐 Find more market coverage at www.benzinga.com 📲 Follow us for real-time updates: 📷 Instagram: @benzinga 👨👩👦📕 Facebook: Benzinga ⏱ TikTo…
Andrew Dudum said this a while ago and I think it still stands true today. Link to watch the original podcast: ...
Honored to have Andrew Dudum take my question on the HIMS Q1 2025 earnings call.
“I would provide every American citizen a HSA FSA type budget of cash that they can then use on service providers to tackle their health. Um that would then create a marketplace dynamic where players like Hims & Hers and everybody else would have to compete. They'd have to compete for the best NPS consumer experience, the most affordable pricing, the best outcomes, the best brand, the ultimately what makes people heal”
“I think ultimately the cost is going to come down dramatically. If you look at the GLP-1s as an example, you know, we we brought those to market at $150, $200 price points per month. At the time, the drug companies were offering those at $1,500 per month. Immense amount of consumer pressure amongst a lot of people resulted now in an environment where you have branded pills, you have vials, you have quick pens all pri”
“I think GLP-1s will have more impact in global society over the next 5 years than AI. No question. And it's not just because somebody's losing 10 pounds, right? The science at this point, the price points of them coming down overseas, they just went generic in Canada this year. They'll go generic in the US in I don't know four years, right? It's already expanding into new form factors with Novo and the pill which unl”
“The drug companies reacted to two different things. One, they reacted to the pricing pressure. So, we were able to manufacture and compound these vials personalized for patients and offer to them for something like $150. The price of the FDA approved medication at the time was $1,500. And so, the pure exposure, the transparency of a model like his and hers where it says, 'Hey, we're consumer oriented. We can make thi”
“We are in the middle right now of breaking how healthcare is distributed entirely. Instead of going through the PBMs and insurance and reimbursements, all of that complexity nobody understands, it will go through consumer channels like Hims & Hers with total price transparency and customer choice.”
“I might be the only person that believes this, but I think running the company in the public markets is more fun than being private. It's like boot camp. You have to deliver.”
Sign in to search the full transcript archive, filter by topic, and access every quote from Andrew Dudum.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans